Template:Second-generation BTKi table: Difference between revisions
From Embryology
mNo edit summary |
mNo edit summary |
||
| Line 1: | Line 1: | ||
{| | {| | ||
|+ '''Novel BTK Inhibitors for CCL Treatment''' | |+ '''Novel BTK Inhibitors for CCL Treatment''' | ||
|- | |-bgcolor="CEDFF2" | ||
! width=120px|BTK inhibitor | ! width=120px|BTK inhibitor | ||
! width=120px|BTK binding mechanism | ! width=120px|BTK binding mechanism | ||
| Line 13: | Line 13: | ||
| N/A | | N/A | ||
| II/III | | II/III | ||
|- | |-bgcolor="F5FAFF" | ||
| Zanubrutinib | | Zanubrutinib | ||
| Covalent, irreversible | | Covalent, irreversible | ||
| Line 25: | Line 25: | ||
| N/A | | N/A | ||
| I/II | | I/II | ||
|- | |-bgcolor="F5FAFF" | ||
| Vecabrutinib | | Vecabrutinib | ||
| Non-covalent, reversible | | Non-covalent, reversible | ||
| Line 37: | Line 37: | ||
| N/A | | N/A | ||
| I | | I | ||
|- | |-bgcolor="F5FAFF" | ||
| ARQ-531 | | ARQ-531 | ||
| Non-covalent, reversible | | Non-covalent, reversible | ||
Revision as of 14:04, 30 April 2019
| BTK inhibitor | BTK binding mechanism | Selectivity for BTK | Relevant non-BTK targets | Phase of clinical development |
|---|---|---|---|---|
| Acalabrutinib | Covalent, irreversible | High | N/A | II/III |
| Zanubrutinib | Covalent, irreversible | Moderate | N/A | II/III |
| Tirabrutinib | Covalent, irreversible | High | N/A | I/II |
| Vecabrutinib | Non-covalent, reversible | Moderate | interleukin-2-inducible (ITK) | I/II |
| LOXO-305 | Non-covalent, reversible | High | N/A | I |
| ARQ-531 | Non-covalent, reversible | Low | Lck/Yes novel tyrosine kinase (LYN), mitogen-activated protein kinase kinase 1 (MEK1) | I |
| Table data [1] | ||||
